Article

3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 71, n° 6
pages 1160-1166 (décembre 2014)
Doi : 10.1016/j.jaad.2014.07.031
accepted : 17 July 2014
Original Articles

Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity
 

Janneke Landheer, MD a, Marjolein de Bruin-Weller, MD, PhD a, Chantal Boonacker, PhD b, DirkJan Hijnen, MD, PhD a, Carla Bruijnzeel-Koomen, MD, PhD a, Heike Röckmann, MD, PhD a,
a Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands 
b Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands 

Reprint requests: Heike Röckmann, MD, PhD, Department of Dermatology, University Medical Center, Heidelberglaan 100, G 02.124, 3584 CX Utrecht, The Netherlands.
Abstract
Background

Serum thymus and activation-regulated chemokine (sTARC) levels reflect disease severity of atopic dermatitis (AD) in small study populations. It remains unclear whether sTARC is a reliable outcome measurement for AD severity in heterogeneous AD populations in daily practice.

Objective

We sought to assess the utility of sTARC as a biomarker for monitoring AD severity in adults in daily practice.

Methods

sTARC, clinical skin score (Six Area, Six Sign AD [SASSAD]), and body surface area measurements were collected from all adult patients with AD visiting our clinic between March 2009 and March 2012, at first visit or exacerbation (baseline). In addition, data from short-term and long-term follow-up visits were collected.

Results

At baseline sTARC levels ranged widely (n = 320; minimum-maximum: 3-50,400 pg/mL) and sTARC and SASSAD or body surface area correlated moderately. In the majority of patients, sTARC and SASSAD or body surface area changed congruently during follow-up.

Limitations

Data were collected retrospectively.

Conclusion

sTARC may represent a suitable biomarker for monitoring of AD severity in daily practice.

The full text of this article is available in PDF format.

Key words : atopic dermatitis, body surface area, disease severity, follow-up, serum thymus and activation-regulated chemokine, Six Area, Six Sign Atopic Dermatitis

Abbreviations used : AD, BSA, SASSAD, SCORAD, sTARC



 Funding sources: None.
 Conflicts of interest: None declared.



© 2014  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline